Share Price | Humacyte, Inc. Stock Analysis & Recommendation

Q: What does Humacyte, Inc. do?

Overview:Humacyte, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot:Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025) Most recent Net Profit: 37 Million (Quarterly Results - Mar 2025) Market cap: USD 361.43 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: 0.18 Return on Equity: -333.22% Price to Book: 10.03Contact Details:Details: No Company Details Available Registrar Address: Not available.

Q: Is Humacyte, Inc. overvalued or undervalued?

As of 14 August 2023, the valuation grade for Humacyte, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial health. The company is currently overvalued, as evidenced by its price-to-book value of 11.15 and negative EV to EBITDA of -3.93, which highlight the lack of profitability and excessive valuation relative to its assets. Additionally, the return on capital employed (ROCE) stands at a staggering -261.68%, and return on equity (ROE) is at -333.22%, further underscoring the company's financial struggles.In comparison to its peers, Humacyte's EV to EBITDA ratio of -3.93 is better than that of uniQure NV at -5.35 and Precigen, Inc. at -3.90, but still reflects a challenging environment for the company. The stock has underperformed significantly against the S&P 500, with a year-to-date return of -56.24% compared to the index's 2.44%, reinforcing the notion that Humacyte is not a viable investment at its current valuation.

Q: Is Humacyte, Inc. technically bullish or bearish?

As of 2 September 2025, the technical trend for Humacyte, Inc. has changed from mildly bearish to bearish. The current stance is bearish with strong indicators supporting this view. The MACD is bearish on both weekly and monthly time frames, and the moving averages are bearish on a daily basis. Additionally, the KST and OBV indicators are bearish on both weekly and monthly time frames, while Bollinger Bands and Dow Theory also indicate a mildly bearish sentiment. In terms of performance, Humacyte has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -64.55% compared to the S&P 500's 12.22%, and a one-year return of -66.48% versus 17.14% for the index.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

13.44 M

Shareholding (Sep 2025)

FII

5.91%

Held by 60 FIIs

DII

80.6%

Held by 21 DIIs

Promoter

0.30%

How big is Humacyte, Inc.?

22-Jun-2025

As of Jun 18, Humacyte, Inc. has a market capitalization of 361.43 million and reported net sales of 0.52 million with a net profit of -80.03 million over the last four quarters. Shareholder's funds are at -52.67 million, with total assets of 137.87 million.

View full answer

What does Humacyte, Inc. do?

22-Jun-2025

Humacyte, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $1 million and a net profit of $37 million as of March 2025. It has a market cap of $361.43 million, with key metrics indicating it is currently loss-making and has a debt-to-equity ratio of 0.18.

View full answer

Is Humacyte, Inc. overvalued or undervalued?

25-Jun-2025

As of August 14, 2023, Humacyte, Inc. is overvalued and has deteriorated to a "does not qualify" rating due to negative profitability metrics, including a price-to-book ratio of 11.15 and a return on equity of -333.22%, while significantly underperforming the S&P 500 with a year-to-date return of -56.24%.

View full answer

Is Humacyte, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, Humacyte, Inc. is in a bearish trend with strong indicators, including negative MACD and moving averages, and has underperformed the S&P 500 significantly, with a year-to-date return of -64.55% compared to the index's 12.22%.

View full answer

Compare Humacyte, Inc. with Similar Stocks

uniQure NV Terns Pharmaceuticals, Inc.Renovaro, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Net Sales has grown by an annual rate of 23.55% and Operating profit at -195.80% over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -13.82

Risky -

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 216 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.80

Return on Equity

2,430.90%

Price to Book

-45.50

Revenue and Profits:

Net Sales:

1 Million

(Quarterly Results - Sep 2025)

Net Profit:

-18 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-24.75%

6 Months

-49.98%

1 Year

-74.39%

2 Years

-74.31%

3 Years

-72.48%

4 Years

-86.42%

5 Years

-92.34%

Humacyte, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

23.55%

EBIT Growth (5y)

-195.80%

EBIT to Interest (avg)

-13.82

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.18

Sales to Capital Employed (avg)

0.03

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

51.97%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-45.50

EV to EBIT

-2.09

EV to EBITDA

-2.24

EV to Capital Employed

-219.94

EV to Sales

140.00

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 32 Schemes (13.18%)

Foreign Institutions

Held by 60 Foreign Institutions (5.91%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 166.67% vs -40.00% in Jun 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 53.58% vs -202.45% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.80",
          "val2": "0.30",
          "chgp": "166.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-22.50",
          "val2": "-27.90",
          "chgp": "19.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.60",
          "val2": "2.50",
          "chgp": "4.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "8.90",
          "val2": "-6.20",
          "chgp": "243.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-17.50",
          "val2": "-37.70",
          "chgp": "53.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-32,390.40%",
          "val2": "-98,760.80%",
          "chgp": "6,637.04%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -34.21% vs -823.33% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-107.20",
          "val2": "-92.30",
          "chgp": "-16.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "9.30",
          "val2": "6.60",
          "chgp": "40.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-29.10",
          "val2": "-12.70",
          "chgp": "-129.13%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-148.70",
          "val2": "-110.80",
          "chgp": "-34.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ

Sep'25

Jun'25

Change(%)

Net Sales

0.80

0.30

166.67%

Operating Profit (PBDIT) excl Other Income

-22.50

-27.90

19.35%

Interest

2.60

2.50

4.00%

Exceptional Items

8.90

-6.20

243.55%

Consolidate Net Profit

-17.50

-37.70

53.58%

Operating Profit Margin (Excl OI)

-32,390.40%

-98,760.80%

6,637.04%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Sep 2025 is 166.67% vs -40.00% in Jun 2025

Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is 53.58% vs -202.45% in Jun 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-107.20

-92.30

-16.14%

Interest

9.30

6.60

40.91%

Exceptional Items

-29.10

-12.70

-129.13%

Consolidate Net Profit

-148.70

-110.80

-34.21%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -34.21% vs -823.33% in Dec 2023

All Annual Results

Company CV

About Humacyte, Inc.

Humacyte, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available